Mr. Lynn D. Torbeck - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Mr. Lynn D. Torbeck


Mr. Lynn D. Torbeck is a Pharmtech editorial advisory board (EAB) member

Mr. Lynn D. Torbeck
Principal Statistician
Torbeck & Associates

Lynn D. Torbeck is a consultant specializing in applied statistics and experimental design for pharmaceutical and biopharmaceutical development, quality assurance and control, validation, and production under the CGMPs. Areas of expertise include quality by design, design space, OOS, SQC/SPC, statistical PAT, assay validation, sampling plans, and setting specification criteria. Torbeck has been active in the pharmaceutical industry in statistics, quality, and management since 1975; he has been president of Torbeck and Assoc., Inc. since 1988. He has worked with a wide variety of companies, including pharmaceuticals, biotechnology, fine chemicals, medical devices, and cosmetics. Torbeck is the author of several books on validation and has published a number of journal articles.

Torbeck has been a member of the Editorial Advisory Board of Pharmaceutical Technology since 1999, and was elected to the PDA Scientific Advisory Board (SAB) in 2002 and the USP Statistics Expert Committee for a second five-year term in 2005. He was chair of the PDA’s SAB Out-Of-Specification committee. He won the PDA TRI Excellence in Teaching Award in 1997 and again in 2007. He is also a member of the ASTM E-11, statistics, and E-55, PAT, committees.

Torbeck is a member of the American Statistical Association, PDA, Senior Member of the American Society for Quality, ASQ, ASTM, and is past president of the Chicago Chapter of the American Statistical Association. He is a past Book Reviews Editor for the Journal of Quality Technology, a publication of the American Society for Quality. He holds an AAS degree in Electronics and BS and MS degrees in Statistics with minors in Operations Research and Computer Science.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
39%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
15%
Less restrictive inventory control by pharmaceutical companies
8%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
Federal Spending Freeze Could Threaten Supply-Chain Security
FindPharma Custom Search

Click here